Sarepta Therapeutics (SRPT) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.13
- Estimate
- $0.36
- Surprise
- -63.6%
- Revenue (period 2026-09-30)
- $323.8M
- Score today
- 5.3/10
Revenue source: xbrl.
How the report landed
Sarepta Therapeutics (SRPT) missed the $0.36 estimate with adjusted EPS of $0.13 — a large 63.6% shortfall.
Coverage in the report window
- Sarepta Therapeutics Q3 2026 Earnings Call Transcript — benzinga, 2026-11-05
- Sarepta Therapeutics Reports Third Quarter 2026 Financial Results — fiscal.ai, 2026-11-05
Where TrendMatrix's rating stands now
TrendMatrix currently rates SRPT Sell at 5.3/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's -63.6% surprise compares with a -48.8% four-quarter average.
What argues against it
- Concentration risk — Product: Duchenne products
- Concentration risk — Supplier: Catalent
- Quality below floor (2.8 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $17.74
- Price target
- $19.47
- Stop
- $16.50
- Upside to target
- +9.8%
- Reward-to-risk
- 0.9:1
Model outputs from TrendMatrix’s engine as of 2026-11-06 — shown for context, not personalized investment advice.
SRPT at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $1.86B
- P/E (fwd)
- 7.2
- 52-week range
- $14.68–$24.68
- Off 52-week high
- 28.1%
- RSI (14)
- 50
- Volume vs avg
- 0.29×
- Score today
- 5.3/10